WST Stock Recent News

WST rides on GLP-1 demand and Annex 1 expansion, but margins face pressure from pricing and tariff headwinds.

West Pharmaceutical Services, Inc. (WST) Presents At Wells Fargo 2025 Healthcare Conference (Transcript)

The mean of analysts' price targets for West Pharmaceutical (WST) points to a 28.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here, we discuss four stocks from the Dental Supplies industry that are likely to generate wealth for investors amid tariff uncertainty. These are MCK, CAH, WST and COO.

West Pharmaceutical Services, Inc.'s Q2 results signal a return to growth, driven by strong demand for high-value products and GLP-1 agonist components. I am revamping my bullish thesis: GLP-1 drugs now provide a powerful, sustained growth catalyst beyond the company's traditional biologics and injectable therapeutics exposure. Risks include elevated valuation, potential competition, and the threat of oral GLP-1 formulations or healthcare policy changes impacting future growth.

The consensus price target hints at a 25.3% upside potential for West Pharmaceutical (WST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of West Pharmaceutical Services, Inc. (NYSE: WST) breached their fiduciary duties to shareholders.

West Pharmaceutical (WST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CALX, MEDP and WST made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 28, 2025.

My estimations suggest that the U.S. government cuts to its healthcare system will not have a significant negative impact on West Pharmaceutical's revenues. In Q2 2025, the company's revenues increased by 9.17%, suggesting that the destocking effect is vanishing. The company has low debt levels, achieving a liabilities-to-assets ratio of 25.90% in Q2 2025. Additionally, it achieved a 17.03% net profit margin in 2024.